Do you know new repellent technology INSECT SHIELD was now launched in Thailand

Food and Healthcare Press Releases Friday July 21, 2017 13:50
Bangkok--21 Jul--ASK CREATION

INSECT SHIELD was developed in USA since 1996 at a request by US Military to terminate Lyme Disease brought by Ticks. As a result of 7 years testing and experiments, now US Army and Marine adopts INSECT SHIELD technology to their uniforms.

INSECT SHIELD repellent technology is effective for Mosquito, Ticks, Lice, Ant and Midget.
INSECT SHIELD repellent has big advantages on PORTABILITY and DURABILITY, with SAFE repellent component to be used for babies, little kids and pregnant women.
For more technical information, please visit our website.
https://insectshieldthailand.wordpress.com/
In 2017 March, INSECT SHIELD® repellent gears came to Thailand to struggle with Dengue fever, Zika virus, and Malaria caused by Mosquito.
Currently, Dengue fever is wide spreading in northern part of Thailand.
Please always go out with INSECT SHIELD.

Latest Press Release

Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method

Study published in Science magazine demonstrates how epigenetic markers can identify cell subtypes and regulatory elements that drive cellular diversity Swift Biosciences, a leading provider of innovative library prep solutions for next-generation...

Making it Easier to Understand Nutrition Labels

The Nutrition Facts label can provide you with lots of useful information—as long as you know how to read it correctly. Reading nutrition labels can be a challenge, because it always seems confusing and complicated. Oftentimes, you are discouraged...

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

- Collaboration furthers both parties' commitment to advance research and development for neglected diseases - Agreement focuses on optimizing vaccine process development and formulation and exchanging know-how Merck , a leading science and technology...

NICE Recommends Erbitux(R) in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity

- Decision secures access to Erbitux(R) for new patients in England with oral cavity tumors - All patients currently receiving Erbitux(R) will have continued access Merck, a leading science and technology company, announced today that the National...

European Patent Office to Grant Merck#s Patent Application for CRISPR Technology

- Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Related patent application recently awarded in Australia; similar patents pending in other countries, favourable outcomes...

Related Topics